Hematologic response to dasatinib
| . | Follow-up for 6 mo, no. (%) . | Follow-up for 8 mo, no. (%) . | ||||
|---|---|---|---|---|---|---|
| Total . | Imatinib-resistant . | Imatinib-intolerant . | Total . | Imatinib-resistant . | Imatinib-intolerant . | |
| All patients | 107 (100) | 99 (100) | 8 (100) | 107 (100) | 99 (100) | 8 (100) |
| CHR | 35 (33) | 33 (33) | 2 (25) | 42 (39) | 39 (39) | 3 (38) |
| NEL | 28 (26) | 25 (25) | 3 (38) | 27 (25) | 25 (25) | 2 (25) |
| Major hematologic response (CHR and NEL) | 63 (59) | 58 (59) | 5 (63) | 69 (64) | 64 (65) | 5 (63) |
| Minor hematologic response | 23 (22) | 22 (22) | 1 (13) | 18 (17) | 16 (16) | 2 (25) |
| Overall hematologic response* | 86 (80) | 80 (81) | 6 (75) | 87 (81) | 80 (81) | 7 (88) |
| No response | 21 (20) | 19 (19) | 2 (25) | 20 (19) | 19 (19) | 1 (13) |
| . | Follow-up for 6 mo, no. (%) . | Follow-up for 8 mo, no. (%) . | ||||
|---|---|---|---|---|---|---|
| Total . | Imatinib-resistant . | Imatinib-intolerant . | Total . | Imatinib-resistant . | Imatinib-intolerant . | |
| All patients | 107 (100) | 99 (100) | 8 (100) | 107 (100) | 99 (100) | 8 (100) |
| CHR | 35 (33) | 33 (33) | 2 (25) | 42 (39) | 39 (39) | 3 (38) |
| NEL | 28 (26) | 25 (25) | 3 (38) | 27 (25) | 25 (25) | 2 (25) |
| Major hematologic response (CHR and NEL) | 63 (59) | 58 (59) | 5 (63) | 69 (64) | 64 (65) | 5 (63) |
| Minor hematologic response | 23 (22) | 22 (22) | 1 (13) | 18 (17) | 16 (16) | 2 (25) |
| Overall hematologic response* | 86 (80) | 80 (81) | 6 (75) | 87 (81) | 80 (81) | 7 (88) |
| No response | 21 (20) | 19 (19) | 2 (25) | 20 (19) | 19 (19) | 1 (13) |
CHR indicates complete hematologic response; NEL, no evidence of leukemia.
Overall hematologic response is defined as the sum of CHR, NEL, and minor hematologic response rates.